Please assess the completion status of the following clinical trial:

Trial Title: Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV infection~* Naïve to Raltegravir.~* CD4 cell count above 200 cell/mm3.~* No history of failure to PI containing regimens.~* No evidence of PI mutations (IAS-mutation list) by genotype test.~* Failing to a NRTI based regimen.~* The treating physician decides a NRTI sparing regimen which includes DRV/r 800/100 mg QD plus Raltegravir 400 mg BID.~* Signed informed consent form~* In opinion of the investigator, the patient should be considered clinically stable and could follow regular visits as scheduled per protocol.~Exclusion Criteria:~* Patients receiving drugs considered contraindicated to Raltegravir and DRV/r. Contraindicated drugs are: rifampin, fenitoin, phenobarbital in the case of raltegravir. Pravastatin, astemizole, sildenafil, are contraindicated in combination with DRV/r.~* Pregnancy~* Documented PI mutations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single arm with dual therapy (Type: None): Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).